This study showed that Tyr641 mutations were linked to a significant decrease in EZH2 enzymatic activity in vitro, in apparent contradiction to the elevated EZH2 mRNA levels seen in breast and prostate cancer. This evidence concerns the gene EZH2 and prostate cancer.